With IPOs not an option, should pharma feed the biotech ecosystem?

This year's J.P. Morgan Healthcare Conference had its share of bright new ideas and pioneering technologies, tempered by the simple reality that key financial trends on tap for 2012 have already been playing out for several tough years. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.